跳转至内容
Merck
CN

C1653

可待因 溶液

analytical standard, for drug analysis, 1.0 mg/mL in methanol

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C18H21NO3
化学文摘社编号:
分子量:
299.36
UNSPSC Code:
41116107
PubChem Substance ID:
EC Number:
200-659-6
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


agency

EPA 1694

drug control

Home Office Schedule 2; stupéfiant (France)

concentration

1.0 mg/mL in methanol

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

application(s)

environmental
pharmaceutical (small molecule)

format

single component solution

storage temp.

2-8°C

SMILES string

[H][C@@]12Oc3c(OC)ccc4C[C@H]5N(C)CC[C@@]1(c34)[C@@]5([H])C=C[C@@H]2O

InChI

1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1

InChI key

OROGSEYTTFOCAN-DNJOTXNNSA-N

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.


Still not finding the right product?

Explore all of our products under 可待因 溶液


flash_point_c

11 °C - closed cup

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

51.8 °F - closed cup

ppe

Eyeshields, Faceshields, Gloves

法规信息

监管及禁止进口产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



K Krause et al.
Allergy, 68(2), 256-258 (2013-01-17)
Platelet-activating factor (PAF) causes wheal and flare responses which are abrogated by H1-antihistamines giving rise to the hypothesis that PAF-induced wheal development is secondary to histamine release from dermal mast cells. But is this hypothesis correct? Wheal and flare responses
Is it farewell to codeine?
Brian J Anderson
Archives of disease in childhood, 98(12), 986-988 (2013-08-27)
Laurence Toms et al.
The Cochrane database of systematic reviews, (1)(1), CD001547-CD001547 (2009-01-23)
This is an updated version of the Cochrane review published in Issue 4, 1998. Combining drugs from different classes with different modes of action may offer opportunity to optimise efficacy and tolerability, using lower doses of each drug to achieve